MDNA.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases...

Stats
Today's Volume	175 850
Average Volume	154 908
Market Cap	135.79M
EPS	$0 ( 2024-02-15 )
Next earnings date	( $-0.0600 ) 2024-06-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.48
ATR14	$0.00700 (0.37%)

Volume Correlation

Long: -0.34 (neutral)

Short: -0.01 (neutral)

Signal:(31.126) Neutral

MEDICENNA THERAPEUTICS Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MEDICENNA THERAPEUTICS Correlation - Currency/Commodity

0.52
( weak )

0.64
( weak )

0.00
( neutral )

-0.48
( neutral )

MEDICENNA THERAPEUTICS Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-5 000.00 (0.00 %)
EPS:	$0.0239

FY	2022
Revenue:	$0
Gross Profit:	$-5 000.00 (0.00 %)
EPS:	$0.0239

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.420

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

MEDICENNA THERAPEUTICS

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.